Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

The VISTA trial is evaluating and comparing 2 dose levels of laru-zova to an untreated control group for the treatment of ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in therapies and expanding indications for treatment. Gene therapy, ...

Sanaregen Vision Therapeutics has made an announcement inviting prospective investors to reserve shares of stock ownership. This comes as the company prepares to launch its equity crowdfunding ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

The Wilmer Eye Institute at Johns Hopkins University School of Medicine in Baltimore, Maryland, has launched a yearlong centennial celebration, marking 100 years of pioneering contributions to ...

A significant change that simplified the patient getting into the exam chair and improved patient-doctor interaction was to move the slit lamp to the patient’s right (Figure). This allowed computer ...